Cathie Wood Funds Jump as Gene Editing Edges Closer to Reality
- ETFs added $1 billion after positive results in Intellia study
- Gains come after a selloff in speculative stocks this year
This article is for subscribers only.
Two Cathie Wood funds are back in the spotlight after adding about $1 billion in market value on Monday following a promising advance in the field of gene editing.
Wood’s Ark Investment Management LLC is a top holder of companies operating in this area after the active investor made an early bet on Crispr Therapeutics AG, Intellia Therapeutics Inc. and Editas Medicine Inc.-- three companies using a technology for editing the human genome called Crispr. Ark is also the second largest holder in Beam Therapeutics Inc., another company working on fixing genetic mutations.